Christine Ring

Chief Legal Officer Christine Ring sells 28,935 shares of NRIX at $20.06 under 10b5-1 plan; retains 13,579 shares plus 134,398 option holdings.

Christine Ring sold 28,935 shares for $580,505.54 via a pre-arranged 10b5-1 trading plan on 2026-06-25, reducing her non-derivative holdings to 13,579 shares post-transaction. This scheduled transaction occurred at $20.06 per share while the current market price stands at $22.46, placing the trade at -2.7% from the 52-week high of $23.09. Ring maintains derivative holdings of 134,398 option shares, meaning her overall economic exposure to NRIX remains substantial despite the share sale. The company reported revenue of $6,252,000.00 in the latest quarter with net income of -$87,174,000.00, reflecting ongoing unprofitability despite annual revenue growth of +54.0%.

CLO Christine Ring sells 37.6K NRIX shares (-42.5% of holdings) at $17.07 amid unprofitability and 80% quarterly surge

Christine Ring, CLO of Nurix Therapeutics, sold 37,600 shares at $17.07, reducing her holdings by 42.5% from 88,497 to 50,897 shares. The sale occurs within a volatile context: the stock has surged 80.0% over 90 days and 54.6% over 30 days, but remains 24.8% below its 52-week high. Nurix reported a net loss of $86.4M on revenue of $7.9M (latest quarter) and experienced annual revenue contraction of 29.2%, indicating the company remains in a pre-profitable biotech phase. The magnitude of the reduction and timing near a 90-day peak warrant attention to whether this reflects capital redeployment or confidence shifts in the company's trajectory.